HK Stock Market Move | ZHAOKE OPHTH-B (06622) has increased by more than 5% and has expanded its partnership agreement with AFT to commercialize BRIMOCHOL PF in Singapore.

ZHAOKE OPHTH-B (06622) rose more than 5%, rising 4.56% as of the time of writing, closing at 3.44 Hong Kong dollars, with a trading volume of 1.707 million Hong Kong dollars. On the news front, on January 26, ZHAOKE OPHTH-B announced that the company has expanded its partnership agreement with leading healthcare product manufacturer and distributor AFT Pharmaceuticals Limited (AFT) to commercialize BRIMOCHOL PF in Singapore. The company has also established a strategic partnership with leading Asian ophthalmic company Chosun Pharmaceutical Co., Ltd. (Chosun) to commercialize the product in Vietnam. ZHAOKE has granted exclusive distribution rights to AFT and Chosun in Singapore and Vietnam, including rights for registration, importation, promotion, distribution, marketing, and sales of BRIMOCHOL PF in the respective markets. Through these agreements, AFT and Chosun become the seventh and eighth commercialization partners for BRIMOCHOL PF, showcasing the company's strong commitment to global expansion. BRIMOCHOL PF is a potential therapy for correcting near vision loss due to presbyopia and is a core asset acquired by the company through its partner Tenpoint Therapeutics, Ltd.